Goodrx Holdings Inc
NASDAQ:GDRX
Goodrx Holdings Inc
NASDAQ:GDRX
Price:
6.97 USD
-0.43%
Market Closed
Updated:
May 2, 2024
Goodrx Holdings Inc
Research & Development
|
Goodrx Holdings Inc
Research & Development Peer Comparison
Comparables:
VEEV
INSP
EVH
DOCS
CERT
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
Research & Development
-$135.8m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Veeva Systems Inc
NYSE:VEEV
|
Research & Development
-$629m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-37%
|
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Research & Development
-$116.5m
|
CAGR 3-Years
-65%
|
CAGR 5-Years
-74%
|
CAGR 10-Years
N/A
|
|
|
Evolent Health Inc
NYSE:EVH
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Doximity Inc
NYSE:DOCS
|
Research & Development
-$80.2m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Certara Inc
NASDAQ:CERT
|
Research & Development
-$34.2m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
See Also
What is Goodrx Holdings Inc's Research & Development?
Research & Development
-135.8m
USD
-135.8m
USD
Based on the financial report for Dec 31, 2023, Goodrx Holdings Inc's Research & Development amounts to -135.8m USD.
What is Goodrx Holdings Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-25%
-25%
Over the last year, the Research & Development growth was 5%. The average annual Research & Development growth rates for Goodrx Holdings Inc have been -30% over the past three years , -25% over the past five years .
You don't have any saved screeners yet
